NextGen Bio
Filter News
Found 6,996 articles
-
BioSpace Hotbed maps have been a life sciences industry staple for over 30 years. Today the program features eight regional Hotbed Maps and the NextGen Bio Map which highlights some of the industry’s most promising startups.
-
BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life science companies in North America that launched no earlier than mid-2018.
-
Upping the numbers two times, Silverback now readies a 10 million share offering.
-
Noema Pharma raised $59 million in a Series A financing round that will support the development of four clinical-stage assets the company licensed from Roche for the treatment of orphan neurological diseases with severe unmet needs.
-
Venture capital investment firm GV, formerly Google Ventures, led the Series A financing round for the company. Other investors contributed to the round but have decided to remain anonymous.
-
Biopharma Money on the Move: November 18-24
11/25/2020
Find out which biopharma companies are raking in cash this week, as companies from around the globe provide updates on their financing rounds and IPOs. -
Kronos Bio Announces Participation in Upcoming Investor Conferences
11/23/2020
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in the following investor conferences: A virtual fireside chat at the Evercore ISI 3 rd Annual HealthCONx Conference on Wednesday, Dec. 2, 2020, at 2:15 p.m. ET; and Meetings at the Piper Sandler 32 nd Annual Virtual Healthcare Conference o
-
Funding raised will be used to take lead candidate into Phase III clinical trials.
-
In the IPO announcement, Olema Oncology notes it has granted the underwriters a 30-day option to buy up to 1,650,000 more common stock shares at the IPO price.
-
Immunotherapies are about to get safer, more effective, and even more accessible with the new biotech’s novel approach.
-
Biopharma Money on the Move: November 11-17
11/18/2020
Find out which biopharma companies are raking in cash this week, as companies from around the globe provide updates on their financing rounds and IPOs. -
Kronos Bio Reports Recent Business Progress and Third Quarter 2020 Financial Results
11/18/2020
Acquired from Gilead Sciences a portfolio of SYK inhibitors, including lead investigational therapy entospletinib being developed for frontline treatment of N PM1-mutated acute myeloid leukemia Expanded executive team and board of directors with hiring of COO and CFO and appointment of audit committee chair, respectively Completed upsized initial public offering of common stock on October 14, 2020, raising $28 7.5 million in gross proceeds
-
Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1
11/16/2020
Collaboration with the Bill & Melinda Gates Foundation Seeks to Bring Forward a New HIV Prevention Option to Help Address the HIV Epidemic with Focus on Women in Sub-Saharan Africa
-
Two new companies exploded onto the scene this morning, backed by significant financing that will be used to develop treatments for a wide range of diseases.
-
Biopharma Money on the Move: November 4-10
11/11/2020
Find out which biopharma companies are raking in cash this week, as companies from around the globe provide updates on their financing rounds and IPOs. -
5AM Ventures and Wu Capital joined existing investors Frazier Healthcare Partners and Jubilant Biosys Limited.
-
Passage Bio Highlights University of Pennsylvania’s Gene Therapy Program’s Newly Published Research to Prevent Toxicity Associated with Gene Therapy
11/11/2020
Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders, today commends the newly published research of the University of Pennsylvania’s (Penn) Gene Therapy Program (GTP) regarding a novel targeted approach to prevent a selective neurotoxicity seen in the sensory neurons of dorsal root ganglia (DRG) after gene therapy treatment. As prev
-
Passage Bio to Participate in Upcoming November Investor Conferences
11/11/2020
Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that management will participate in two upcoming virtual investor conferences in November. Guggenheim Virtual Healthcare Talks: 2nd Annual Neuro/Immunology Day Date: Monday, November 16, 2020 Stifel Virtual Healthcare Conference Date: Wednesday, November
-
Hot 12 Biotech Companies Hiring Now
11/10/2020
According to BioSpace research, only 48% of biotech professionals feel there is a career development path for all employees at their current company. Do you have a career development path? -
Gossamer Bio Announces Third Quarter 2020 Financial Results and Provides Corporate Update
11/10/2020
GB004: SHIFT-UC Phase 2 trial enrolling patients with active ulcerative colitis (UC) - - GB002: TORREY Phase 2 trial activated in patients with pulmonary arterial hypertension (PAH) - - GB1275: Two posters with data from ongoing Phase 1/2 KEYNOTE-A36 clinical trial in advanced solid tumors presented at Society for Immunotherapy of Cancer Meeting 2020 -